The Effects of Probiotic Supplementation on Clinical Symptom, Weight Loss, Glycemic Control, Lipid and Hormonal Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials

被引:0
作者
Reza Tabrizi
Vahidreza Ostadmohammadi
Maryam Akbari
Kamran B. Lankarani
Sina Vakili
Payam Peymani
Maryam Karamali
Fariba Kolahdooz
Zatollah Asemi
机构
[1] Shiraz University of Medical Sciences,Health Policy Research Center, Institute of Health, Student Research Committee
[2] Kashan University of Medical Sciences,Research Center for Biochemistry and Nutrition in Metabolic Diseases
[3] Shiraz University of Medical Sciences,Health Policy Research Center
[4] Shiraz University of Medical Sciences,Department of Biochemistry
[5] Iran University of Medical Sciences,Department of Gynecology and Obstetrics, School of Medicine
[6] University of Alberta,Indigenous and Global Health Research, Department of Medicine
来源
Probiotics and Antimicrobial Proteins | 2022年 / 14卷
关键词
Probiotic; Weight loss; Glycemic control; Lipids profiles; Inflammation; Oxidative markers; Meta-analysis; Polycystic ovary syndrome;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of this systematic review and meta-analysis of randomized controlled trials (RCTs) is to determine the effectiveness of probiotic supplementation on clinical symptoms, weight loss, glycemic control, lipid and hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome (PCOS). Eligible studies were systematically searched from Cochrane Library, Embase, Medline, and Web of Science databases until January 2019. Cochran (Q) and I-square statistics were used to measure heterogeneity among included studies. Data were pooled by using random-effect model and expressed as standardized mean difference (SMD) with 95% confidence interval (CI). Eleven articles were included in this meta-analysis. Probiotic supplementation significantly decreased weight (SMD − 0.30; 95% CI, − 0.53, − 0.07; P = 0.01), body mass index (BMI) (SMD − 0.29; 95% CI, − 0.54, − 0.03; P = 0.02), fasting plasma glucose (FPG) (SMD − 0.26; 95% CI, − 0.45, − 0.07; P < 0.001), insulin (SMD − 0.52; 95% CI, − 0.81, − 0.24; P < 0.001), homeostatic model assessment for insulin resistance (HOMA-IR) (SMD − 0.53; 95% CI, − 0.79, − 0.26; P < 0.001), triglycerides (SMD − 0.69; 95% CI, − 0.99, − 0.39; P < 0.001), VLDL-cholesterol (SMD − 0.69; 95% CI, − 0.99, − 0.39; P < 0.001), C-reactive protein (CRP) (SMD − 1.26; 95% CI, − 2.14, − 0.37; P < 0.001), malondialdehyde (MDA) (SMD − 0.90; 95% CI, − 1.16, − 0.63; P < 0.001), hirsutism (SMD − 0.58; 95% CI, − 1.01, − 0.16; P < 0.001), and total testosterone levels (SMD − 0.58; 95% CI, − 0.82, − 0.34; P < 0.001), and also increased the quantitative insulin sensitivity check index (QUICKI) (SMD 0.41; 95% CI, 0.11, 0.70; P < 0.01), nitric oxide (NO) (SMD 0.33; 95% CI 0.08, 0.59; P = 0.01), total antioxidant capacity (TAC) (SMD 0.64; 95% CI, 0.38, 0.90; P < 0.001), glutathione (GSH) (SMD 0.26; 95% CI, 0.01, 0.52; P = 0.04), and sex hormone binding globulin (SHBG) levels (SMD 0.46; 95% CI, 0.08, 0.85; P = 0.01). Probiotic supplementation may result in an improvement in weight, BMI, FPG, insulin, HOMA-IR, triglycerides, VLDL-cholesterol, CRP, MDA, hirsutism, total testosterone, QUICKI, NO, TAC, GSH, and SHBG but did not affect dehydroepiandrosterone sulfate levels, and total, LDL, and HDL cholesterol levels in patients with PCOS.
引用
收藏
页码:1 / 14
页数:13
相关论文
共 214 条
  • [1] Fauser BC(2012)Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group Fertil Steril 97 28-38
  • [2] Tarlatzis BC(2018)Contemporary approaches to the management of polycystic ovary syndrome Ther Adv Endocrinol Metab 9 123-134
  • [3] Rebar RW(2010)What have we learned form monogenic forms of severe insulin resistance associated with PCOS/HAIRAN? Ann Endocrinol (Paris) 71 222-224
  • [4] Legro RS(2012)Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications Endocr Rev 33 981-1030
  • [5] Balen AH(2017)New therapeutic approaches in obesity and metabolic syndrome associated with polycystic ovary syndrome Cureus 9 e1844-319
  • [6] Lobo R(2014)The effect of obesity on inflammatory markers in patients with PCOS: a BMI-matched case-control study Arch Gynecol Obstet 290 315-2165
  • [7] Carmina E(2004)Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease J Clin Endocrinol Metab 89 2160-440
  • [8] Chang J(2015)Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials Ann Med 47 430-5836
  • [9] Yildiz BO(2017)Effects of new probiotic mouthwash in patients with diabetes mellitus and cardiovascular diseases Eur Rev Med Pharmacol Sci 21 5827-311
  • [10] Laven JS(2018)The probiotic supplementation reduced inflammation in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial J Funct Foods 42 306-406